• Latest Posts

Legochem Bioscience signs agreement with Glycotope to develop cancer drug

Spirea raises £2.4M to develop antibody drug conjugates in cancer

Tubulis Rides Investment Wave in ADCs with €60M Series B

ADC Approval Buoys Spirits in Cancer Treatment Space

Update: Chinese Pharma Enlists Synaffix’s ADC Technology for Second Drug

Update: Swiss Biotech’s Series E Expanded to €271M to Commercialize Antibody-Guided Cancer Chemotherapy

Interview 25 Oct 2018

Mastering the Competitive World of Immuno-oncology

Update: Yet Another ADC Company Makes Bank, This Time in Series B

New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients

German Biotech Reels in €34M for its Cancer-Killing Technology

Interview 4 Oct 2017

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

More News! 20 Sep 2017

New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer